In molecular mechanisms such as innate immune resistance, the results of this in vitro investigation suggests that PD-L1 may be downregulated by decreased MSH6 expression in pituitary tumors, which could lead to a tumor microenvironment that facilitates tumor immunity in pituitary tumors. The gene discussed is MSH6; the disease is neoplasm.